AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03729648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Arts Therapy
Description: The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
Study NCT04058444 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
Study NCT04026321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 125mL/day
Description: SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study NCT04026321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 250mL/day
Description: SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study NCT04026321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 500mL/day
Description: SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study NCT04026321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ001 625mL/day
Description: SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study NCT04026321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
Study NCT02724358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: iodized oil (5ml) + Pirarubicin (20mg)
Study NCT02724358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rg3
Description: 20mg, BID, maintained though Month 12.
Study NCT02724358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACE + Rg3
Study NCT02724358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protective therapy
Description: standard liver protective therapy
Study NCT04642716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva collection of patients and salivary free amino acids analysis
Study NCT03677765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra- vs Infraclavicular approach using ultrasonography
Description: In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
Study NCT03958383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2
Description: A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
Study NCT03958383 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Palliative radiation therapy
Study NCT03958383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human programmed death receptor (PD-1) blocking antibody, given IV
Study NCT03958383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
Study NCT02519608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
Study NCT02519608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
Study NCT02519608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
Study NCT02519608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
Study NCT02602093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Endoscopic Discectomy
Description: Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
Study NCT02602093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Microdiscectomy
Description: General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
Study NCT02484066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
Study NCT02484066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VBN
Description: VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
Study NCT02484066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT02484066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT02484066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
Study NCT03065777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONE ENDO
Description: single file rotary system
Study NCT03065777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F6 SKYTaper
Description: single file rotary system
Study NCT03065777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProTaper Universal
Description: multi-file rotary system
Study NCT04146168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
Study NCT00981149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
Study NCT00981149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match duloxetine for 6 week period.
Study NCT03432507 — intervention group
Intervention type: OTHER
Intervention: PCR
Description: PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
Study NCT02925897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change and motivational interviewing
Description: nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
Study NCT04034823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 5 mg/kg s.c. Q3W
Study NCT04034823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg IV loading followed by 6 mg/kg Q3W IV
Study NCT04034823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 Q3W IV
Study NCT01844388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose based eye drop formula
Description: 1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
Study NCT01844388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based eye drop solution
Description: 1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
Study NCT04012580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-assisted ICBT
Description: An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
Study NCT02884388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined nerve block
Description: Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
Study NCT02884388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Patients in this group were assigned to receive general anesthesia.
Study NCT02055898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Study NCT02055898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo (fresh potable water)
Study NCT03371472 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visualisation and measuring of paravalvular leak.
Description: Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
Study NCT01030029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical auricular acupuncture
Description: Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point \[2\]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
Study NCT01030029 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: P-Stim™ devices were applied without electrical stimulation and acupuncture.
Description: Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
Study NCT03992079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReCOVER Enhanced Recovery Protocol
Description: The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
Study NCT01507922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoverine
Description: Fenoverine 100mg three times a day for 8 weeks
Study NCT01507922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timebutine
Description: Timebutine maleate 150mg three times a day for 8 weeks
Study NCT02649140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinegar group
Description: Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
Study NCT00358397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium novyi-NT spores
Study NCT00756249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24493 (CEPO)
Description: 0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
Study NCT00756249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vials with solution for IV infusion
Study NCT01349517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MIE
Description: The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
Study NCT01349517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Three-incision thoracotomy
Description: The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
Study NCT01349517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ivor-Lewis esophagectomy
Description: The patients in this group would underwent Ivor-Lewis esophagectomy
Study NCT01349517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sweet esophagectomy
Description: The patients in this group would underwent Sweet esophagectomy.
Study NCT00557921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin
Description: (CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Study NCT00557921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix (clopidogrel 75 mg) and aspirin
Description: (CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
Study NCT00688259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy (ST)
Description: approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
Study NCT00688259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Psychosis (CBTp)
Description: approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
Study NCT03153514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v.~\[Day 0 = day of stem cell transplant\]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)
Study NCT00965081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
Study NCT00965081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD po at the same time each day for 12 weeks
Study NCT02060435 — intervention group
Intervention type: OTHER
Intervention: EBER
Description: EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
Study NCT04713280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary posterior dento-alveolar intrusion
Description: Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
Study NCT04713280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary posterior dento-alveolar intrusion
Description: Mini-screw supported maxillary or bi-maxillary posterior dento-alveolar intrusion
Study NCT02004353 — intervention group
Intervention type: DEVICE
Intervention: Cochlear® Hearing Implants
Description: Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
Study NCT01566253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen, ketoprofen, morphine
Description: Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
Study NCT02418871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.
Study NCT02418871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Performed using standard microsurgical techniques
Study NCT01147666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arms.
Study NCT01566253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, ketoprofen,morphine
Description: Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
Study NCT01350739 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraumbilical incision
Description: vertical, intraumbilical incision
Study NCT01350739 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: infraumbilical incision
Description: incision at the inferior boarder of the umbilicus, circular
Study NCT01147666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin Alfa will be administered per dose and schedule specified in the arms.
Study NCT01147666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to roxadustat will be administered per schedule specified in the arm.
Study NCT00730977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dry powder inhaled mannitol
Description: single doses of 40 mg, 70 mg and 100 mg
Study NCT03596827 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E. coli strain E1392-75-2A dose 1E10 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
Study NCT03596827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E9 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
Study NCT03596827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E8 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
Study NCT03596827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E7 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
Study NCT01303029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine+erlotinib
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Study NCT03596827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli strain E1392-75-2A dose 1E6 CFU
Description: Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat